Three health organisations have appointed 17 leading international scientists to advise on its £50 million investment into type 1 diabetes research. 
The Steve Morgan Foundation, Diabetes UK and JDRF UK are recruiting for its Type 1 Diabetes Grand Challenge – a project that is funding research to drive breakthroughs in type 1 diabetes treatments and lead the race towards a cure.
The scientists have joined one of three independent Scientific Advisory Panels each advising on a research area identified as having the greatest potential to transform treatments for type 1 diabetes.
These include:
All three panels are chaired by the world-renowned diabetes specialist Professor Simon Heller.
Rachel Connor, Director of Research Partnerships at JDRF UK, said: “We’re delighted to welcome so many globally renowned scientists, who are already giving us the benefit of their insight and expertise as we shape this Grand Challenge.
“They are ensuring the research we support through this game-changing partnership will best meet the needs of people living with type 1.”
She added: “The calibre of membership we’ve been able to attract to the new panels is testament to how thrilling the new research, supported by the partnership, will be.”
Dr Elizabeth Robertson, Director of Research at Diabetes UK, said: “We are honored to have so many of the world’s most distinguished diabetes researchers advising the Type 1 Diabetes Grand Challenge.
“Their expertise will help to ensure that every penny of the Steve Morgan Foundation’s £50 million gift is invested in bold, innovative research with the greatest potential to improve the lives of people with type 1 diabetes.”
She concluded: “We’re delighted to see the global research community united in their support of the Type 1 Diabetes Grand Challenge and look forward to seeing new, exciting research focusing on accelerating progress towards a cure for type 1 diabetes get underway next year.”
Further information on the Grand Challenge’s scope and ambition, and membership of the Scientific Advisory Panels, can be found on the Partnership’s new website.
The site also features latest Grand Challenge news, information about funding opportunities and funded projects, and – when research projects are underway – it will demonstrate and celebrate their impact.
Register an account or login to comment
Diabetes UK issues latest guidance on coronavirus
People with diabetes urged to be ‘particularly stringent’ amid COVID-19 pandemic
NHS Drug Tariff approval for FreeStyle Libre System
Updated metformin and B12 guidance published
Criticism over Eatwell Plate amid calls for low carb approach
Type 1 man no longer requires insulin
Man commended for living with diabetes for 80 years
Warning over Lucozade sugar reduction
FreeStyle® Libre 2 includes optional real-time alarms
Novo Nordisk UK launches Ozempic® (semaglutide)
Antihyperglycaemic drugs are beneficial for people with type 2 diabetes and chronic obstructive pulmonary disease
Global scientific experts to advise on £50 million investment into type 1 diabetes research
Once-weekly semaglutide helps combat teenage obesity, evidence identifies
Retired optometrist puts diabetes technologies under the spotlight in latest Big Interview
Welsh type 2 diabetes patients are missing out on vital free education
New book on type 1 diabetes technology published
Leading diabetes conference gives ‘vital boost’ to care
FDA approves first drug that can delay onset of type 1 diabetes
Once-weekly semaglutide is a ‘cost-effective’ treatment option for type 2 diabetes, study shows
JDRF appoints new chair
Band 7 Midwife in Diabetes
Advanced Podiatrist in Diabetes
Paediatric Diabetes Dietitian
Diabetes Specialist Nurse
Consultant in Diabetes and Endocrinology
Diabetes Support Worker (South West & South Central)
Digital Engagement Officer (South West & South Central)
Diabetic Specialist Midwife
Paediatric Diabetes Clinical Nurse Specialist & Transitional Care Lead
Diabetes Nurse Specialist
This website is certified by Health On the Net Foundation. Click to verify.
The Diabetes Times © 2022


By admin

Leave a Reply

Your email address will not be published. Required fields are marked *